angiotensin ii has been researched along with tamoxifen in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Lenz, T | 1 |
| Acharya, A; Lei, J; Neugarten, J; Silbiger, S | 1 |
| Brosnihan, KB; Herrington, DM; Hollenberg, NK; Jeunemaitre, X; Okamura, K; Seely, EW; Williams, GH | 1 |
| Dueñas-Rodríguez, B; Martínez-Martos, JM; Ramírez-Exposito, MJ | 1 |
| Abo-Saif, AA; El-Sayed El-Daly, M; Moustafa Ahmed, Y; Shehata Messiha, BA | 1 |
| Azizian, H; Bashiri, H; Ebrahimi, MN; Khaksari, M; Raji-Amirhasani, A | 1 |
| Andrique, C; Bonnet, AL; Chaussain, C; Gaucher, C; Gomila, C; Hague, F; Kamel, S; Kowalewski, C; Krautzberger, AM; Lenglet, G; Lesieur, J; Louvet, L; Mahtal, N; Mentaverri, R; Schrewe, H; Six, I; Tharaux, PL | 1 |
| Bottermann, K; Deenen, R; Fischer, JW; Gödecke, A; Grandoch, M; Harris, TE; Hemmers, A; Herebian, D; Kalfhues, L; Köhrer, K; Leitner, LM; Nederlof, R; Nemmer, J; Oenarto, V; Petzsch, P; Pfeffer, M; Raje, V; Reichert, AS; Stegbauer, J; Zabri, H | 1 |
1 trial(s) available for angiotensin ii and tamoxifen
| Article | Year |
|---|---|
Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women.
Topics: Aged; Angiotensin I; Angiotensin II; Blood Pressure; Cross-Over Studies; Double-Blind Method; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Linear Models; Middle Aged; Postmenopause; Renal Circulation; Renin-Angiotensin System; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
8 other study(ies) available for angiotensin ii and tamoxifen
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Release of prorenin and placental hormones from superfused minced chorion laeve.
Topics: Analysis of Variance; Angiotensin II; Cesarean Section; Chorion; Diltiazem; Enzyme Precursors; Estradiol; Female; Humans; In Vitro Techniques; Mifepristone; Placenta; Pregnancy; Progesterone; Renin; Tamoxifen | 1997 |
Selective estrogen receptor modulators suppress mesangial cell collagen synthesis.
Topics: Angiotensin II; Animals; Cell Line, Transformed; Collagen; Endothelin-1; Estrogen Receptor beta; Estrogens; Glomerular Mesangium; Mice; Mice, Inbred Strains; Mitogen-Activated Protein Kinases; Pyrrolidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Transcription Factor AP-1; Transcription, Genetic; Transforming Growth Factor beta; Up-Regulation | 2000 |
Circulating renin-angiotensin system-regulating specific aminopeptidase activities in pre- and post- menopausal women with breast cancer treated or not with neoadyuvant chemotherapy. A two years follow up study.
Topics: Aminopeptidases; Angiotensin II; Anthracyclines; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; CD13 Antigens; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Glutamyl Aminopeptidase; Humans; Immunotherapy; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Postmenopause; Premenopause; Radiotherapy, Adjuvant; Renin-Angiotensin System; Tamoxifen | 2019 |
Effects of ticagrelor, empagliflozin and tamoxifen against experimentally-induced vascular reactivity defects in rats in vivo and in vitro.
Topics: AMP-Activated Protein Kinase Kinases; Angiotensin II; Animals; Aorta; Arthritis, Rheumatoid; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Endothelium, Vascular; Female; Glucosides; Nitric Oxide; Nitric Oxide Synthase Type III; Protein Kinases; Purinergic P2 Receptor Antagonists; Rats; Rats, Inbred WF; Receptors, Purinergic P2Y12; Selective Estrogen Receptor Modulators; Sodium-Glucose Transporter 2 Inhibitors; Tamoxifen; Ticagrelor; Vascular Cell Adhesion Molecule-1; Vasodilation | 2019 |
Protective effects of combining SERMs with estrogen on metabolic parameters in postmenopausal diabetic cardiovascular dysfunction: The role of cytokines and angiotensin II.
Topics: Angiotensin II; Animals; Cytokines; Diabetes Mellitus, Type 2; Estrogens; Female; Interleukin-10; Postmenopause; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Necrosis Factor-alpha | 2022 |
Vasorin plays a critical role in vascular smooth muscle cells and arterial functions.
Topics: Angiotensin II; Animals; Apoptosis Regulatory Proteins; Calcium; Carbachol; Humans; Membrane Proteins; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitric Oxide; Phenylephrine; Tamoxifen | 2022 |
Cardiomyocyte p38 MAPKα suppresses a heart-adipose tissue-neutrophil crosstalk in heart failure development.
Topics: Adipose Tissue; Angiotensin II; Animals; Cardiomegaly; Fatty Acids; Heart Failure; Inflammation; Lipase; Lipids; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Neutrophils; p38 Mitogen-Activated Protein Kinases; Tamoxifen | 2022 |